UK's Linde Q4 revenue and adjusted EPS beat estimates on volume growth

Reuters
02/05
UK's Linde Q4 revenue and adjusted EPS beat estimates on volume growth 

Overview

  • Industrial gases firm's Q4 revenue beat analyst expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company returned $2.1 bln to shareholders through dividends and stock repurchases

Outlook

  • Linde expects Q1 2026 adjusted EPS of $4.20 to $4.30

  • Linde forecasts full-year 2026 adjusted EPS of $17.40 to $17.90

  • Company plans $5.0 bln to $5.5 bln in 2026 capital expenditures

Result Drivers

  • PRICE AND VOLUME GROWTH - Linde's Q4 sales increased 6% YoY, driven by 2% price attainment and 1% volume growth from project startups

  • PRODUCTIVITY INITIATIVES - Adjusted operating profit rose 4% due to productivity initiatives across all segments

  • REGIONAL PERFORMANCE - Americas sales rose 8% driven by higher pricing and volumes, while EMEA saw a decline in underlying sales due to lower volumes

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$8.80 bln

$8.64 bln (15 Analysts)

Q4 Adjusted EPS

Beat

$4.20

$4.18 (18 Analysts)

Q4 EPS

$3.26

Q4 Adjusted EBIT

Beat

$2.60 bln

$2.56 bln (14 Analysts)

Q4 EBIT

$2 bln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the commodity chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Linde PLC is $500.50, about 5.7% above its February 4 closing price of $473.33

  • The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nEQ8C6V0Ta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10